Daniel Cabo
Spain
Research Article
Beneficials Effects of Canagliflozin in a Weight-Centered Management in Patients with Type 2 Diabetes Mellitus in Real Practice
Author(s): Florentino Carral, Manuel Cayón, Ana Isabel Jiménez and Daniel CaboFlorentino Carral, Manuel Cayón, Ana Isabel Jiménez and Daniel Cabo
Objective: Evaluate the real-world efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus (T2DM), associated to a weight-loss intensive lifestyle intervention program (WLIP), to achieve weight loss greater than 5% at 12 months.
Methods: Retrospective review of patients with T2DM included in a WLIP, who were prescribed canagliflozin from June 2015 to December 2016 at four endocrinology clinics in the south of Spain within routine clinical practice context. Changes during 12 months in anthropometric variables, HbA1c, uric acid and adverse events were assessed.
Results: 201 patients with T2DM (45.8% women, 60.3 ± 9.4 years old and BMI: 34.9 ± 8.7 kg/m2) were studied. Patients treated with canagliflozin lost an average weight and reduced an average of waist circumference of -4.0 ±.. View More»
